AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Moderna's stock falls after the FDA vows to impose new vaccine rules. The FDA aims to standardize vaccine trials and boost transparency, sparking concerns about potential delays and increased costs for vaccine development. Moderna's shares drop 3.6% amid the news, while the company's CEO, Stéphane Bancel, emphasizes the importance of innovation and flexibility in vaccine development.

Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet